https://pubmed.ncbi.nlm.nih.gov/38113437

The erratum does not provide new information and does not change the conclusions of the original study, which found that tislelizumab was not superior to chemotherapy as a second-line treatment for advanced or metastatic esophageal squamous cell carcinoma.